医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Numurkah District Health Service Improves Safety with Spok’s Clinical Alerting Solution

2014年11月13日 AM11:00
このエントリーをはてなブックマークに追加


 

PERTH, Western Australia

Spok, Inc. today announced that Numurkah District Health Service in Victoria, Australia, is using the Spok® clinical alerting solution to improve staff safety and efficiency.

A leading community health provider, Numurkah has created an alerting hub using the Spok solution, which prioritises notifications from clinical and safety systems and relays them to the right on-duty staff member for fast resolution. The solution helps staff address alerts rapidly while improving both patient and employee safety. In addition, the Spok solution’s extensive capabilities and complete audit trail enable new workflow efficiencies throughout the hospital, which is key to meeting Australia’s National Safety and Quality Health Service (NSQHS) standards.

The clinical alerting solution also lets staff send duress alarms from their Cisco® wireless IP phones to the correct team to accelerate response time. Moreover, it allows the originator of the duress call to have greater confidence in the outcome knowing assistance is on the way. The solution also improves patient care through integration with the nurse call and fire panel systems. For example, when a patient pushes the nurse call button, the Spok solution automatically sends an alert including the patient’s location to the appropriate caregiver on his or her smartphone or Cisco wireless IP phone.

Numurkah District Health Service partnered with Spok and its local reseller, ArchiTech, and technology partner, Olinqua, to create the best overall messaging solution for the facility.

“Numurkah’s use of the Cisco duress alarm notifications is an innovative solution which puts safety at the forefront of these facilities. This, in concert with the mobile device alerts from the nurse call and fire panel systems, introduces time-saving measures that improve health and safety conditions for both patients and staff,” said John Jordan, Spok’s regional vice president – APAC. “We were pleased to work with our partners ArchiTech and Olinqua on this project, which allowed us to implement this new approach to alerting within the Numurkah healthcare system.”

About Numurkah District Health Service

Numurkah District Health Service is a leader in rural health and community services in Australia. It offers a range of health programs for the community, including acute care, urgent care, surgical, district nursing, allied and primary health, and residential aged care services. Numurkah is an innovative organisation which is always looking for ways to enhance patient care and safety for those in the community.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), is proud to be a leader in critical communications for healthcare, government, public safety, and other industries. We deliver smart, reliable solutions to help protect the health, well-being, and safety of people around the globe. More than 125,000 organisations worldwide rely on Spok for workflow improvement, secure texting, paging services, contact centre optimisation, and public safety response. When communications matter, Spok delivers. Visit us at spok.com/apac or find us on Twitter @Spok_APAC.

Spok is a trademark of Spok Holdings. Cisco is a trademark of Cisco Systems, Inc.

CONTACT

Spok, Inc.
Jill Asby, +1 952-230-5363
jill.asby@spok.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)